| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10591747 | Bioorganic & Medicinal Chemistry Letters | 2013 | 19 Pages |
Abstract
Using structure-based drug design, we identified and optimized a novel series of pyrimidodiazepinone PLK1 inhibitors resulting in the selection of the development candidate TAK-960. TAK-960 is currently undergoing Phase I evaluation in adult patients with advanced solid malignancies.
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Zhe Nie, Victoria Feher, Srinivasa Natala, Christopher McBride, Andre Kiryanov, Benjamin Jones, Betty Lam, Yan Liu, Stephen Kaldor, Jeffrey Stafford, Kouki Hikami, Noriko Uchiyama, Tomohiro Kawamoto, Yuichi Hikichi, Shin-ichi Matsumoto, Nobuyuki Amano,